Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Shares Outstanding (Weighted Average): 2009-2024

Historic Shares Outstanding (Weighted Average) for Ironwood Pharmaceuticals (IRWD) over the last 16 years, with Dec 2024 value amounting to $160.0 million.

  • Ironwood Pharmaceuticals' Shares Outstanding (Weighted Average) rose 1.69% to $162.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $162.4 million, marking a year-over-year increase of 1.69%. This contributed to the annual value of $160.0 million for FY2024, which is 2.50% up from last year.
  • Ironwood Pharmaceuticals' Shares Outstanding (Weighted Average) amounted to $160.0 million in FY2024, which was up 2.50% from $156.1 million recorded in FY2023.
  • Ironwood Pharmaceuticals' Shares Outstanding (Weighted Average)'s 5-year high stood at $163.7 million during FY2021, with a 5-year trough of $153.4 million in FY2022.
  • Its 3-year average for Shares Outstanding (Weighted Average) is $156.5 million, with a median of $156.1 million in 2023.
  • Its Shares Outstanding (Weighted Average) has fluctuated over the past 5 years, first increased by 2.64% in 2020, then declined by 6.27% in 2022.
  • Ironwood Pharmaceuticals' Shares Outstanding (Weighted Average) (Yearly) stood at $161.0 million in 2020, then climbed by 1.67% to $163.7 million in 2021, then decreased by 6.27% to $153.4 million in 2022, then grew by 1.78% to $156.1 million in 2023, then grew by 2.50% to $160.0 million in 2024.